

26 October 2016

## Japan Patent Office Issues Notice of Acceptance of Microarray Skincare Patent

**OBJ Limited (ASX: OBJ)** has received notice that the Japan Patent Office (JPO) has issued a Notice of Acceptance of OBJ's magnetic microarray skincare patent.

A Notice of Acceptance is the final approval stage and precedes actual granting which is expected shortly. The patent identification is Japanese Patent Application 2013-514498

The granting of this patent by the US Patent Office (USPTO) was also announced recently, with prosecution of the same patent application continuing in Europe.

As with the patent granted by the USPTO, the JPO patent has a life of 20 years from the earliest filing date of the application. OBJ expects it to be highly valued by SK-II, the Japan-based brand commercialising the microarray technology.

The added benefit of patent protected market exclusivity adds further value to the measurable improvement in product performance the microarray technology provides to P&G. P&G has exclusive rights to use OBJ's microarray technology for its skincare products in the beauty and grooming market.

This new patent acceptance further expands OBJ's growing portfolio of granted intellectual property protection that now includes:

- Skincare microarray – granted in USA, accepted in Japan
- Programmable array – granted in USA, UK, France and Germany
- Skincare device and fabric care – granted in Australia
- Oral care microarray – granted in USA and Japan

### About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

### About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

#### Directors

Mr Glyn Denison  
Mr Jeffrey Edwards  
Dr Chris Quirk

#### Company Secretary

Mr John Palermo

#### Registered Office:

284 Oxford Street  
Leederville  
Western Australia 6007  
Tel: +61 8 9443 3011  
Fax: +61 8 9443 9960  
www.obj.com.au  
ABN: 72 056 482 636

26 October 2016

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

## Forward-Looking Statements

---

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

**For more information:**

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Phone:** +61 451 896 420